Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

1.

Targeting the right regulatory T-cell population for tumor immunotherapy.

Weiss VL, Lee TH, Jaffee EM, Armstrong TD.

Oncoimmunology. 2012 Oct 1;1(7):1191-1193.

PMID:
23170276
[PubMed]
Free PMC Article
2.

Rapamycin promotes the enrichment of CD4(+)CD25(hi)FoxP3(+) T regulatory cells from naïve CD4(+) T cells of baboon that suppress antiporcine xenogenic response in vitro.

Singh AK, Horvath KA, Mohiuddin MM.

Transplant Proc. 2009 Jan-Feb;41(1):418-21. doi: 10.1016/j.transproceed.2008.10.079.

PMID:
19249569
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Regulatory T cells in tumor immunity.

Nishikawa H, Sakaguchi S.

Int J Cancer. 2010 Aug 15;127(4):759-67. doi: 10.1002/ijc.25429. Review.

PMID:
20518016
[PubMed - indexed for MEDLINE]
4.

Targeting tumor-related immunosuppression for cancer immunotherapy.

Frumento G, Piazza T, Di Carlo E, Ferrini S.

Endocr Metab Immune Disord Drug Targets. 2006 Sep;6(3):233-7. Review.

PMID:
17017974
[PubMed - indexed for MEDLINE]
5.

A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.

Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54.

PMID:
17671115
[PubMed - indexed for MEDLINE]
Free Article
6.

Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells.

Kunzmann V, Kimmel B, Herrmann T, Einsele H, Wilhelm M.

Immunology. 2009 Feb;126(2):256-67. doi: 10.1111/j.1365-2567.2008.02894.x. Epub 2008 Sep 2.

PMID:
18775028
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.

Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML.

J Immunol. 2006 Jul 1;177(1):84-91.

PMID:
16785502
[PubMed - indexed for MEDLINE]
Free Article
8.

TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy.

Amiset L, Fend L, Gatard-Scheikl T, Rittner K, Duong V, Rooke R, Muller S, Bonnefoy JY, Préville X, Haegel H.

Oncoimmunology. 2012 Nov 1;1(8):1271-1280.

PMID:
23243590
[PubMed]
Free PMC Article
9.

Regulatory T cells in gastrointestinal tumors.

Raghavan S, Quiding-Järbrink M.

Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):489-501. doi: 10.1586/egh.11.44. Review.

PMID:
21780896
[PubMed - indexed for MEDLINE]
10.

Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.

Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA.

PLoS One. 2010 Jul 22;5(7):e11726. doi: 10.1371/journal.pone.0011726.

PMID:
20668510
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response.

Singh AK, Seavey CN, Horvath KA, Mohiuddin MM.

Xenotransplantation. 2012 Mar-Apr;19(2):102-11. doi: 10.1111/j.1399-3089.2012.00697.x.

PMID:
22497512
[PubMed - indexed for MEDLINE]
12.

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.

Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F.

Eur J Immunol. 2004 Feb;34(2):336-44.

PMID:
14768038
[PubMed - indexed for MEDLINE]
13.

TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function.

Nyirenda MH, Sanvito L, Darlington PJ, O'Brien K, Zhang GX, Constantinescu CS, Bar-Or A, Gran B.

J Immunol. 2011 Sep 1;187(5):2278-90. doi: 10.4049/jimmunol.1003715. Epub 2011 Jul 20.

PMID:
21775683
[PubMed - indexed for MEDLINE]
Free Article
14.

CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.

Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, Xue J, Zhang FM, Ge HL, Xu D.

Clin Immunol. 2009 Apr;131(1):109-18. doi: 10.1016/j.clim.2008.11.010. Epub 2009 Jan 18.

PMID:
19153062
[PubMed - indexed for MEDLINE]
15.

Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.

Nagayama Y, Hase W, Motoyoshi Y, Saitoh O, Sogawa R, Nakao K.

Oncol Rep. 2007 May;17(5):1269-73.

PMID:
17390075
[PubMed - indexed for MEDLINE]
16.

Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo.

Nitcheu-Tefit J, Dai MS, Critchley-Thorne RJ, Ramirez-Jimenez F, Xu M, Conchon S, Ferry N, Stauss HJ, Vassaux G.

J Immunol. 2007 Aug 1;179(3):1532-41.

PMID:
17641019
[PubMed - indexed for MEDLINE]
Free Article
18.

Suppression of alloimmunity in mice by regulatory T cells converted with conditioned media.

Teng L, Liu L, Su Y, Yuan X, Li J, Fu Q, Chen S, Wang C.

J Surg Res. 2011 Dec;171(2):797-806. doi: 10.1016/j.jss.2010.03.044. Epub 2010 Apr 15.

PMID:
20538297
[PubMed - indexed for MEDLINE]
19.

Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.

Ruter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W, Curiel TJ.

Front Biosci (Landmark Ed). 2009 Jan 1;14:1761-70. Review.

PMID:
19273160
[PubMed - indexed for MEDLINE]
20.

Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites.

Chaput N, Darrasse-Jèze G, Bergot AS, Cordier C, Ngo-Abdalla S, Klatzmann D, Azogui O.

J Immunol. 2007 Oct 15;179(8):4969-78.

PMID:
17911581
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk